Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Cash from Financing Activities (2017 - 2024)

Solid Biosciences' Cash from Financing Activities history spans 7 years, with the latest figure at $6.9 million for Q4 2024.

  • For Q4 2024, Cash from Financing Activities rose 1274.26% year-over-year to $6.9 million; the TTM value through Dec 2024 reached $122.4 million, up 62.73%, while the annual FY2024 figure was $122.4 million, 3821.75% up from the prior year.
  • Cash from Financing Activities for Q4 2024 was $6.9 million at Solid Biosciences, up from $3.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $135.2 million in Q1 2021 and bottomed at -$238000.0 in Q2 2021.
  • The 4-year median for Cash from Financing Activities is $505000.0 (2023), against an average of $25.6 million.
  • The largest YoY upside for Cash from Financing Activities was 113137.88% in 2022 against a maximum downside of 133.33% in 2022.
  • A 4-year view of Cash from Financing Activities shows it stood at $66000.0 in 2021, then surged by 113137.88% to $74.7 million in 2022, then plummeted by 99.32% to $505000.0 in 2023, then skyrocketed by 1274.26% to $6.9 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Cash from Financing Activities are $6.9 million (Q4 2024), $3.3 million (Q3 2024), and $5.0 million (Q2 2024).